A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole (Femara®), in women who have gone through menopause and have received treatment for hormone receptor-positive early breast cancer. Participants must have completed at least five years of hormone therapy with at least two of those years with letrozole before starting their participation in the study. Women who have completed four years of hormone therapy are also eligible if their doctor considers them at low risk of cancer returning.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta po menopauzie
- •Waga co najmniej 50 kg, wskaźnik BMI między 19 a 39
- •Potwierdzona diagnoza raka piersi wrażliwego na hormony, wczesny stadium
- •Ukończone co najmniej 5 lat terapii hormonalnej, w tym co najmniej 2 lata letrozolem
- •Dobry stan zdrowia ogólny
- •Badanie piersi (mammografia) w ciągu ostatnich 12 miesięcy bez śladów raka
✗ Disqualifies
- •Nieskontrolowana poważna choroba interna
- •Stosowanie hormonów estrogenowych lub progesteronu w ciągu ostatnich 3 miesięcy
- •Zdiagnozowana osteoporoza
- •Choroby serca w przeszłości
- •Pozytywny wynik na wirusowe zapalenie wątroby B lub C, lub HIV
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- October 9, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (21)
Precision NextGen Oncology and Research Center (Investigational Site number USA-001)
Beverly Hills, United States
D&H National Research Centers INC (Investigational Site number USA-002)
Margate, United States
United Medical Research (Investigational Site number USA-005)
Port Orange, United States
Investigational Site number SRB-004
Belgrade, Serbia
Investigational Site number SRB-002
Belgrade, Serbia
Investigational Site number SRB-001
Kamenitz, Serbia
Investigational Site number SRB-003
Kragujevac, Serbia
Investigational Site number SRB-005
Niš, Serbia
Hospital Universitario Fundación Alcorcón (Investigational Site number ESP-015)
Alcorcón, Spain
NEXT Oncology. Phase I Unit / IOB - Hospital Quironsalud Barcelona (Investigational Site number ESP-002)
Barcelona, Spain
Hospital Universitario Virgen de las Nieves (Investigational Site number ESP-011)
Granada, Spain
Hospital Universitario de Jaén (HUJ) (Investigational Site number ESP-005)
Jaén, Spain
Complejo Asistencial Universitario de León - Hospital de León (Investigational Site number ESP-013)
León, Spain
Hospital Universitario Arnau de Vilanova de Lleida (Investigational Site number ESP-003)
Lleida, Spain
Althaia Xarxa Assistencial Universitària de Manresa F.P (Investigational Site number ESP-012)
Manresa, Spain
Hospital Quirónsalud Málaga (Investigational Site number ESP-001)
Málaga, Spain
Hospital Clínico Universitario Virgen de la Arrixaca (Investigational Site number ESP-009)
Murcia, Spain
NEXT Oncology Phase I Unit - Hospital Universitario Quironsalud Madrid (Investigational Site number ESP-008)
Pozuelo de Alarcón, Spain
Hospital Universitari Sant Joan de Reus (Investigational Site number ESP-004)
Reus, Spain
Consorci Corporació Sanitària Parc Taulí - Hospital de Sabadell (Investigational Site number ESP-006)
Sabadell, Spain
Hospital Clinico Universitario Santiago de Compostela (Investigational Site number ESP-007)
Santiago de Compostela, Spain
Trial contact
Clinical Operations. Laboratorios Farmacéuticos ROVI
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.